Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy

Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy

Abstract Background Breast cancer is one of the most lethal cancers in women. Despite significant advances in the diagnosis and treatment of breast cancer, many patients still succumb to this disease, and thus, novel effective treatments are urgently needed. Natural product coumarin has been broadly...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Sujie Zhu, Wenjing Zhu, Kaihua Zhao, Jie Yu, Wenxia Lu, Rui Zhou, Shule Fan, Weikaixin Kong, Feifei Yang, Peipei Shan
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	BMC 2024-07-01
Reeks:	Cell Communication and Signaling
Onderwerpen:	Breast cancer Metastasis Tumor growth Histone deacetylases inhibitor Coumarins FOSL2
Online toegang:	https://doi.org/10.1186/s12964-024-01733-4

Gelijkaardige items

The Role of HDACs as Leukemia Therapy Targets using HDI
door: Ahmad Ahmadzadeh, et al.
Gepubliceerd in: (2016-02-01)

KLF14 inhibits tumor progression via FOSL1 in glioma
door: Xiaohua Wang, et al.
Gepubliceerd in: (2025-03-01)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
door: Feifei Yang, et al.
Gepubliceerd in: (2019-07-01)

Influence of FOSL1 Inhibition on Vascular Calcification and ROS Generation through Ferroptosis via P53-SLC7A11 Axis
door: Sisi Shao, et al.
Gepubliceerd in: (2023-02-01)

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
door: Donglu Wu, et al.
Gepubliceerd in: (2020-11-01)

NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1
door: Carolina Marques, et al.
Gepubliceerd in: (2021-08-01)

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS
door: Adrian Vallejo, et al.
Gepubliceerd in: (2017-05-01)

FOSL1 promotes tumor growth and invasion in ameloblastoma
door: Gan Xiong, et al.
Gepubliceerd in: (2022-09-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
door: Wanli Zhang, et al.
Gepubliceerd in: (2025-02-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
door: Anton Frühauf, et al.
Gepubliceerd in: (2021-08-01)

PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway
door: Haobo Wang, et al.
Gepubliceerd in: (2025-01-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
door: Jie Wang, et al.
Gepubliceerd in: (2022-12-01)

Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway
door: Mingyue Tan, et al.
Gepubliceerd in: (2023-11-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
door: Saikat Dewanjee, et al.
Gepubliceerd in: (2021-05-01)

FOSL1 is a key regulator of a super-enhancer driving TCOF1 expression in triple-negative breast cancer
door: Qingling He, et al.
Gepubliceerd in: (2024-11-01)

FOSL2 activates TGF‐β1‐mediated GLUT1/mTOR signaling to promote diabetic kidney disease
door: Xuelin He, et al.
Gepubliceerd in: (2025-02-01)

The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
door: Edoardo Cellupica, et al.
Gepubliceerd in: (2023-07-01)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
door: Jacob King, et al.
Gepubliceerd in: (2021-11-01)

HDAC3 and HDAC8 are required for cilia assembly and elongation
door: Seon-ah Park, et al.
Gepubliceerd in: (2019-08-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
door: Elizabeth A. Thomas
Gepubliceerd in: (2014-05-01)

HDAC1-mediated deacetylation of HIF1α prevents atherosclerosis progression by promoting miR-224-3p-mediated inhibition of FOSL2
door: Hao Wang, et al.
Gepubliceerd in: (2021-03-01)

FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system
door: Xiaolong Liu, et al.
Gepubliceerd in: (2025-03-01)

MiR-33a targets FOSL1 and EN2 as a clinical prognostic marker for sarcopenia by glioma
door: Wei Wang, et al.
Gepubliceerd in: (2022-08-01)

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies
door: Santiago García, et al.
Gepubliceerd in: (2020-11-01)

Current HDAC Inhibitors in Clinical Trials
door: Elisabetta Di Bello, et al.
Gepubliceerd in: (2022-05-01)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
door: Na Zhao, et al.
Gepubliceerd in: (2020-02-01)

CircCRIM1 promotes nasopharyngeal carcinoma progression via the miR-34c-5p/FOSL1 axis
door: Weifeng He, et al.
Gepubliceerd in: (2022-04-01)

Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
door: Lukas von Bredow, et al.
Gepubliceerd in: (2022-03-01)

Exploration of quinazoline-tethered hydroxamic acid derivatives as HDAC inhibitors for anticancer activity: Design, synthesis, molecular docking, and biological evaluation
door: Shweta Mishra, et al.
Gepubliceerd in: (2024-01-01)

Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding
door: Bernardina Scafuri, et al.
Gepubliceerd in: (2020-12-01)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
door: Beatriz Silva Urias, et al.
Gepubliceerd in: (2022-10-01)

Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase
door: Joonhyeok Choi, et al.
Gepubliceerd in: (2022-01-01)

Overexpression of FRA1 (<i>FOSL1</i>) Leads to Global Transcriptional Perturbations, Reduced Cellular Adhesion and Altered Cell Cycle Progression
door: Wuroud Al-khayyat, et al.
Gepubliceerd in: (2023-09-01)

Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
door: Liesbeth Everix, et al.
Gepubliceerd in: (2023-02-01)

HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription Factor SP1, Potentiating BMP9-Induced Angiogenesis
door: Chen Sun, et al.
Gepubliceerd in: (2024-03-01)

Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation
door: Nhu Truong, et al.
Gepubliceerd in: (2024-01-01)

Design, synthesis, and biological evaluation of substituted benzyl-triazolopyridine derivatives as non-hydroxamate based HDAC8 inhibitors
door: N.V.M. Rao Bandaru, et al.
Gepubliceerd in: (2025-04-01)

The replication timing program in the hands of two HDACs
door: Kazumasa Yoshida, et al.
Gepubliceerd in: (2014-07-01)

Emerging role of HDAC11 in skeletal muscle biology
door: Jihong Chen, et al.
Gepubliceerd in: (2024-05-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
door: Masumeh Sanaei, et al.
Gepubliceerd in: (2019-01-01)